Where to Buy CJC-1295 in Australia (Research Guide)

The short answer

CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue. In Australia it is treated as a prescription-only substance under the Poisons Standard, which means it is not something a member of the public can lawfully obtain over the counter for personal use. It is also not an approved therapeutic good listed on the Australian Register of Therapeutic Goods (ARTG), and growth-hormone-releasing factors are prohibited in sport by the World Anti-Doping Agency (WADA).

For these reasons, CJC-1295 offered by Australian peptide suppliers is positioned as a laboratory research compound only. It is not for human or animal use, not for therapeutic use, and not for use in sport. If you are sourcing it, the practical question is not a dosing question, it is a quality and provenance question: can the supplier evidence what is actually in the vial.

What CJC-1295 is

CJC-1295 is a synthetic peptide modelled on growth-hormone-releasing hormone, a signalling molecule the body uses to communicate with the pituitary gland. As a GHRH analogue, it is studied in a research context for how it interacts with the GHRH receptor. The description here is mechanistic and neutral, and nothing on this page should be read as a claim that the compound does anything beneficial, therapeutic or performance-related in people.

Two forms are commonly referred to in the literature and in supplier catalogues:

The two common forms

• CJC-1295 with DAC (Drug Affinity Complex). The DAC modification is designed to extend the molecule's circulating half-life in study models.
• CJC-1295 without DAC, often called Modified GRF 1-29 or Mod GRF 1-29. This form lacks the DAC modification and is characterised in research as having a shorter half-life.

Because the two forms are chemically distinct, their names, batch records and certificates of analysis should make clear exactly which one a vial contains. Ambiguous labelling that does not specify DAC or no-DAC is itself a quality signal worth noting.

Regulatory status in Australia

Australia regulates medicines and poisons through the Poisons Standard, also known as the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP), administered by the Therapeutic Goods Administration (TGA). CJC-1295 is handled as a Schedule 4 (Prescription Only Medicine) type substance, consistent with how growth-hormone-releasing peptides are scheduled. Schedule 4 substances are available only through a prescription from an authorised prescriber and are not sold freely to the public.

CJC-1295 is also not registered on the ARTG as an approved therapeutic good. That means there is no TGA-approved CJC-1295 medicine. It has not been evaluated and approved by the TGA for safety, quality or efficacy as a treatment for anything.

Regulatory classifications are reviewed and updated over time. Always check the current Poisons Standard and TGA guidance rather than relying on a summary, and treat the exact schedule and any appendix entries as something to verify directly at the source.

WADA and sport status

In the context of competitive sport, CJC-1295 is prohibited. The WADA Prohibited List places growth hormone-releasing factors, including GHRH and its analogues, in the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Substances in S2 are prohibited at all times, meaning both in-competition and out-of-competition.

This matters even outside elite sport, because many community, club and masters competitions adopt the WADA framework. Any athlete subject to anti-doping rules should treat GHRH analogues as prohibited and seek guidance from their national anti-doping organisation. This is a factual note on sport eligibility, not an endorsement of use.

What "buying for research" actually means

Research-use-only (RUO) is not a loophole or a slogan. It describes material supplied strictly for laboratory and research purposes, not for administration to humans or animals, not for therapeutic use, and not for use in sport. Reputable research suppliers state this plainly, and the framing is reflected throughout their labelling, documentation and terms.

When a product is positioned as research-use-only, the questions that matter change entirely. There is no human protocol, no dosage and no cycle to discuss. What remains relevant is provenance: identity, purity, consistency between batches, and whether the supplier can evidence all of it. The rest of this guide focuses on exactly those signals.

The research-use-only frame

• For laboratory research purposes only
• Not for human or veterinary use
• Not a therapeutic good and not a treatment for any condition
• Not for use in sport or any activity governed by anti-doping rules

How to evaluate a research-peptide supplier

The single most useful thing a research buyer can do is judge a supplier on documentation rather than on marketing. Quality compounds come with paperwork that stands up to scrutiny, and the absence of that paperwork is the clearest warning sign of all. Use the checklist below as a baseline.

Signals of a credible research supplier

• A current Certificate of Analysis (CoA) for the specific batch, not a generic or undated document, matched to the lot number on the vial.
• A stated purity percentage, with the analytical method named, so the figure can be understood in context.
• Third-party or independent laboratory testing, so the result is not purely the seller's own claim. Independent verification carries more weight than an in-house number alone.
• Batch and lot records that let you trace a specific vial back to a specific production and testing run.
• Correct handling and storage guidance for the material, and evidence the product has been stored and shipped appropriately.
• Clear, accurate labelling that specifies the exact compound (for example, with DAC versus no-DAC), the quantity, and the research-use-only status.
• Australian-based dispatch and a verifiable business presence, which simplifies accountability and reduces the risks that come with unmarked cross-border parcels.

When you request a Certificate of Analysis, confirm that the batch number on the certificate matches the batch on the vial you receive. A CoA that cannot be tied to the physical product in front of you does not tell you what you have actually bought.

Judge a research supplier by what they can evidence, not by what they claim. The certificate, the batch number and the independent test are the product.

Quality and purity red flags

Problems in the research-peptide market tend to show up the same way: missing documentation, vague labelling, and claims that cannot be checked. The warning signs below are reasons to slow down and ask more questions before sourcing anything.

Red flags worth noting

• No Certificate of Analysis, or a CoA that is generic, undated, or cannot be matched to the batch you receive.
• A purity claim with no named testing method and no independent verification.
• Labelling that does not specify the exact form (DAC versus no-DAC) or the quantity in the vial.
• Therapeutic, performance or anti-ageing claims, or any human dosing guidance, which are inconsistent with genuine research-use-only supply.
• No batch or lot traceability, so you cannot connect a vial to a production and testing record.
• No verifiable business identity, no Australian dispatch details, and no clear terms.
• Prices or claims that are inconsistent with the documentation actually provided.

Responsible-use and legal note

CJC-1295 is a scheduled substance in Australia, is not an approved therapeutic good, and is prohibited in sport. Material offered by research suppliers is for laboratory research purposes only and is not intended for human or animal use. Nothing on this page describes a protocol, a dose or a therapeutic use, because none is appropriate for a research-use-only compound.

Regulations change, and your individual obligations depend on your circumstances and location within Australia. Before sourcing any scheduled substance, confirm the current Poisons Standard entry, check ARTG status at the source, and seek independent professional advice where relevant. Anyone subject to anti-doping rules should consult their national anti-doping organisation.

Frequently asked questions